The Middle East Gazette
SEE OTHER BRANDS

The top news stories from the Middle East

The Middle East Gazette: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Middle East Gazette.

Press releases published on July 22, 2025

Headwater Gold and OceanaGold Sign Letter of Intent to Explore Three Projects in Nevada

Headwater Gold and OceanaGold Sign Letter of Intent to Explore Three Projects in Nevada

VANCOUVER, British Columbia, July 22, 2025 (GLOBE NEWSWIRE) -- Headwater Gold Inc. (CSE: HWG, OTCQB: HWAUF) (the "Company" or "Headwater") is pleased to announce it has signed a non-binding Letter of Intent (“LOI”) with a subsidiary of OceanaGold …

Titan Mining Closes Landmark US$15.8M Credit Agreement with US EXIM

Titan Mining Closes Landmark US$15.8M Credit Agreement with US EXIM

GOUVERNEUR, New York and VANCOUVER, British Columbia, July 22, 2025 (GLOBE NEWSWIRE) -- Titan Mining Corporation (TSX: TI; OTCQB: TIMCF) (“Titan” or the “Company”) is pleased to announce that its wholly owned subsidiary, Empire State Mines, LLC (“ESM”), …

Bitcoin Solaris Announces Final Genesis Event Offering: $1 Token Price for Last 100 Participants

Bitcoin Solaris Announces Final Genesis Event Offering: $1 Token Price for Last 100 Participants

TALLINN, Estonia, July 22, 2025 (GLOBE NEWSWIRE) -- Every altcoin season brings surprises. Some coins pump on pure hype. Others, like Bitcoin Solaris, are building real momentum by delivering on tech, scalability, and accessibility. The crypto market is …

Telix Reports $204M Revenue, Up 63% YOY

Telix Reports $204M Revenue, Up 63% YOY

MELBOURNE, Australia and INDIANAPOLIS, July 22, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today provides an update on its commercial and operational performance for the quarter ended 30 June 2025 (Q2 2025). All …

Scancell reports Phase 2 data showing strongly improved outcomes in Late-Stage Melanoma with its Immunobody® iSCIB1+

Scancell reports Phase 2 data showing strongly improved outcomes in Late-Stage Melanoma with its Immunobody® iSCIB1+

SCOPE trial of SCIB1/iSCIB1+ plus standard of care shows excellent results encompassing efficacy, durability, immune responses and safety Overall response rate for iSCIB1+ was 69% for target HLA type patients, representing 80% of total patients - greatly …

Aura Announces S&P Global Upgrades Outlook to Positive B+ Rating on Larger Scale and Financial Performance

Aura Announces S&P Global Upgrades Outlook to Positive B+ Rating on Larger Scale and Financial Performance

ROAD TOWN, British Virgin Islands, July 21, 2025 (GLOBE NEWSWIRE) -- Aura Minerals Inc. (Nasdaq: AUGO) (TSX: ORA) (B3: AURA33) (“Aura” or the “Company”) today announced that S…

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions